Genmab — August 2020
-
Netop Solsen. Og JW har jo indikeret at de har set virkning i PD-L1 og PD1 refrac patienter:-)
-
Jeg tror store kapitalforvaltere køber på disse niveauer, for at være med i dette gilde...
-
altså det kommende PD-L1x4-1BB gilde...
-
Næsten alle analytikere er kørt over. Pånær UBS og 2-3 US analytikere
-
Der har i øvrigt opdateret deres Investor's Fact Sheet https://www.genmab.com/wp-content/uploads/2020/08/200820_Investor-Fact-Sheet.pdf
-
Og jeg opdaterede "Products and Pipeline" i nat på wiki. Resten af beskrivelse af GEN er dog nogle år gammel, såeee måske nogen havde lyst til at bidrage... https://en.wikipedia.org/wiki/Genmab
-
På Genmabs hjemmeside er ordlyden: Novartis is now responsible for the development and commercialization of ofatumumab in all potential indications. Genmab is entitled to potential regulatory and sales milestones, in addition to 10 percent royalty payment of net sales. Novartis is fully responsible for all costs associated with developing and commercializing ofatumumab
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind